Canada Fusion Biopsy Market Size & Outlook, 2023-2030

The fusion biopsy market in Canada is expected to reach a projected revenue of US$ 65.4 million by 2030. A compound annual growth rate of 6.3% is expected of Canada fusion biopsy market from 2024 to 2030.

Revenue, 2023 (US$M)
$42.6
Forecast, 2030 (US$M)
$65.4
CAGR, 2024 - 2030
6.3%
Report Coverage
Canada

Canada fusion biopsy market highlights

  • The Canada fusion biopsy market generated a revenue of USD 42.6 million in 2023 and is expected to reach USD 65.4 million by 2030.
  • The Canada market is expected to grow at a CAGR of 6.3% from 2024 to 2030.
  • In terms of segment, transrectal was the largest revenue generating biopsy route in 2023.
  • Transperineal is the most lucrative biopsy route segment registering the fastest growth during the forecast period.


Fusion biopsy market data book summary

Market revenue in 2023USD 42.6 million
Market revenue in 2030USD 65.4 million
Growth rate6.3% (CAGR from 2023 to 2030)
Largest segmentTransrectal
Fastest growing segmentTransperineal
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTransrectal, Transperineal
Key market players worldwideKoninklijke Philips NV, Hitachi Ltd, Esaote, Eigen, MedCom, Koelis, Focal Healthcare, UC Care


Other key industry trends

  • In terms of revenue, Canada accounted for 6.8% of the global fusion biopsy market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. fusion biopsy market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 357.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Fusion Biopsy Market Companies

Name Profile # Employees HQ Website

Canada fusion biopsy market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fusion biopsy market will help companies and investors design strategic landscapes.


Transrectal was the largest segment with a revenue share of 87.32% in 2023. Horizon Databook has segmented the Canada fusion biopsy market based on transrectal, transperineal covering the revenue growth of each sub-segment from 2018 to 2030.


Prostate cancer is very common in Canada, with 58 men diagnosed with the disease and 11 related deaths each day. The prevalence of prostate cancer is expected to increase further, owing to the rapidly growing geriatric population.


In addition, increasing awareness among the Canadian population regarding a higher survival rate linked to early diagnosis has contributed to the growth in demand for diagnostic services related to prostate cancer. This can create greater opportunities for new companies looking to enter the market.


For instance, in September 2018, ExactVu, a leader in high-resolution ultrasound technologies, announced Health Canada’s clearance for FusionVu, which enables precise and real time visualization of MRI lesions on micro-ultrasound.

Reasons to subscribe to Canada fusion biopsy market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Canada fusion biopsy market databook

  • Our clientele includes a mix of fusion biopsy market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Canada fusion biopsy market , including forecasts for subscribers. This country databook contains high-level insights into Canada fusion biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Canada fusion biopsy market size, by biopsy route, 2018-2030 (US$M)

Canada Fusion Biopsy Market Outlook Share, 2023 & 2030 (US$M)

Canada fusion biopsy market size, by biopsy route, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more